Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
Theratechnologies to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.